Entrada Therapeutics, Inc.

NasdaqGM:TRDA 株式レポート

時価総額:US$578.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Entrada Therapeutics バランスシートの健全性

財務の健全性 基準チェック /66

Entrada Therapeuticsの総株主資本は$269.4M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$510.8Mと$241.5Mです。 Entrada Therapeuticsの EBIT は$23.7Mで、利息カバレッジ比率-1.4です。現金および短期投資は$327.4Mです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオ-5.5x
現金US$469.75m
エクイティUS$429.93m
負債合計US$152.04m
総資産US$581.96m

財務の健全性に関する最新情報

Recent updates

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

財務状況分析

短期負債: TRDAの 短期資産 ( $414.2M ) が 短期負債 ( $173.9M ) を超えています。

長期負債: TRDAの短期資産 ( $414.2M ) が 長期負債 ( $67.5M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: TRDAは負債がありません。

負債の削減: TRDA過去 5 年間負債を抱えていません。

債務返済能力: TRDAには負債がないため、営業キャッシュフロー でカバーする必要はありません。

インタレストカバレッジ: TRDAには負債がないため、利息支払い の負担は問題になりません。


貸借対照表


健全な企業の発掘